Functional Neuroimaging in Depression

• Status: Completed
• Trial end date: 2009-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Oral administration of escitalopram during 8 weeks; PET scan with 18F-FDG at inclusion and after 8 weeks

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Ghent
• Collaborators: Fund for Scientific Research, Flanders, Belgium; H. Lundbeck A/S
• Treatments: Citalopram; Dexetimide

Criteria

Inclusion Criteria:

• Major Depression, Depressive episode, following DSM-IV criteria

• MADRS-score > 25

• Age: 18-65 yrs

• Medication-free or anti-depressant wash-out 7 days (for fluoxetine: 6 weeks)

• Lorazepam 1mg or zolpidem 10mg are allowed

Exclusion Criteria:

• Suicidality

• Bipolar disorder, following DSM-IV criteria

• Psychotic symptoms

• Substance abuse

• Personality disorder, following DSM-IV criteria

• Cognitive dysfunction due to trauma capitis or dementia

• Diabetes mellitus

• Women without contraceptive protection, with pregnancy or breast feeding

• Pharmacological treatment or ingestion of substance that can influence cerebral perfusion less than a month before inclusion

• IQ below 80

• Conditions not compatible with SPC